Trastuzumab-related cardiac events in the treatment of early breast cancer.
about
Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort studyA Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes.Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registryIncidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis.How does trastuzumab treatment affect the right ventricle in females with breast cancer?Evaluation of QTc Interval Prolongation in Breast Cancer Patients after Treatment with Epirubicin, Cyclophosphamide, and Docetaxel and the Influence of Interobserver Variation.Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival.
P2860
Q34441749-4866B163-1AAB-4C44-866D-E256F116D9F5Q35880224-F461B826-3343-4706-8BF5-D1EDC42E40F7Q36116313-B17C3AA9-1229-437C-AEAD-DCD77E802927Q36900970-94BBBC19-F317-47CE-B8A1-9EE382B15A2DQ37158620-D3F54C41-285E-4767-9AC8-2B244B3E2015Q37592520-26254245-073D-41D2-ABA2-6C04E900647CQ37687943-C60118E7-D644-4F27-8188-1795BF383817Q38639456-671D962A-C282-46CA-A0D9-297AB0E6BBA1Q38992588-33773487-D624-4A0E-9F1F-AE3195F03444Q39178080-7C132325-2DD2-467B-9414-EEF9F1438691Q42318401-4DA97134-C821-4B20-81CA-F5E59E082A61Q50355427-8968FD7A-989D-4AFB-BB22-B478BDA13D60Q51132740-E55C7DF0-0EE3-47FC-BF77-54D728BD1579
P2860
Trastuzumab-related cardiac events in the treatment of early breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Trastuzumab-related cardiac events in the treatment of early breast cancer.
@en
Trastuzumab-related cardiac events in the treatment of early breast cancer.
@nl
type
label
Trastuzumab-related cardiac events in the treatment of early breast cancer.
@en
Trastuzumab-related cardiac events in the treatment of early breast cancer.
@nl
prefLabel
Trastuzumab-related cardiac events in the treatment of early breast cancer.
@en
Trastuzumab-related cardiac events in the treatment of early breast cancer.
@nl
P2093
P2860
P1476
Trastuzumab-related cardiac events in the treatment of early breast cancer.
@en
P2093
Georgeta Fried
Mor Moskovitz
Tslil Regev
P2860
P2888
P356
10.1007/S10549-013-2732-6
P407
P577
2013-10-24T00:00:00Z